DNA X regains Nasdaq equity compliance; monitor period through Aug 2027

DNA X, Inc.

Received Nasdaq Panel letter on Aug 28, 2026 confirming compliance with Listing Rule 5550(b)(1) ($2.5M stockholders' equity requirement).
Securities remain subject to delisting if compliance not maintained until Nov 18, 2026.
Mandatory panel monitor until Aug 28, 2027; new non-compliance triggers delisting determination without cure period.
Company may request hearing with Panel if delisting is proposed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.